Transgenic animal model for alzheimer's disease

US8022268B2 · kind B2 · utility

Assignee

• Universitat Zurich · CH

Inventors

• Jan Grimm · Stintenberger Straße, CH
• Roger Nitsch · Zumikon, CH
• Marlen Knobloch · Tolochenaz, CH
• Uwe Konietzko · Konstanz, DE
• Markus Rudin · Eglisau, CH
• Thomas Müggler · Basel, CH
• Felicitas Kranz · Zürich, CH

Key dates

• Filing date: Jun 11, 2008
• Grant date: Sep 20, 2011
• Expiry date: Jan 11, 2030

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2830/85
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided is a novel APP (amyloid precursor protein) transgenic non-human animal modeling in vivo the pathophysiological effects and effects on cognitive behavior of early intraneuronal and extracellular brain parenchymal amyloid-β (Aβ) deposition and cerebral amyloid angiopathy associated with brain microhemorrhages and reduced vasoreactivity and blood flow. Furthermore, methods of screening for therapeutic or diagnostic agents useful in the treatment or diagnosis of Alzheimer's disease, in particular for improving blood flow to the brain are provided as well as the corresponding therapeutic methods.